China Pharma (CPHI) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 13, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Entity Central Index Key	0001106644
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		43,579,557
Entity File Number	001-34471
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 1,813,544	$ 1,074,979
Restricted cash	222,996	109,908
Banker's acceptances	11,251	45,756
Trade accounts receivable, less allowance for doubtful accounts of $17,342,097 and $17,575,100, respectively	595,733	635,371
Other receivables, less allowance for doubtful accounts of $23,715 and $22,729, respectively	86,065	46,643
Advances to suppliers	277,900	404
Inventory	3,852,972	3,588,824
Prepaid expenses	397,374	77,120
Total Current Assets	7,257,835	5,579,005
Property, plant and equipment, net	15,631,653	16,313,827
Operating lease right of use asset	90,289	136,779
Intangible assets, net	185,244	205,611
TOTAL ASSETS	23,165,021	22,235,222
Current Liabilities:
Trade accounts payable	1,025,098	1,366,330
Accrued expenses	180,719	189,880
Other payables	3,753,356	3,560,332
Advances from customers	592,961	505,398
Other payables - related parties	2,152,161	2,071,986
Operating lease liability, current portion	93,510	91,306
Current portion of construction loan facility	2,118,794	2,150,168
Current portion of lines of credit	1,200,650
Bankers' acceptance notes payable	222,996	109,908
Total Current Liabilities	11,340,245	10,045,308
Non-current Liabilities:
Construction loan facility	1,977,541	2,150,168
Lines of credit, net of current portion	706,264
Operating lease liability, net of current portion		48,701
Deferred tax liability	742,450	753,444
Total Liabilities	14,766,500	12,997,621
Commitments and Contingencies (Note 14)
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580
Additional paid-in capital	23,590,204	23,590,204
Accumulated deficit	(26,620,246)	(25,972,402)
Accumulated other comprehensive income	11,384,983	11,576,219
Total Stockholders' Equity	8,398,521	9,237,601
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 23,165,021	$ 22,235,222

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts	$ 17,342,097	$ 17,575,100
Other receivables, less allowance for doubtful accounts	$ 23,715	$ 22,729
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	43,579,557	43,579,557
Common stock, shares outstanding	43,579,557	43,579,557

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 3,770,723	$ 2,569,408	$ 5,534,678	$ 5,498,681
Cost of revenue	2,620,925	2,405,860	4,190,441	4,678,603
Gross profit	1,149,798	163,548	1,344,237	820,078
Operating expenses:
Selling expenses	727,642	505,866	1,053,737	984,557
General and administrative expenses	322,445	334,550	711,004	763,367
Research and development expenses	30,044	66,008	78,863	135,926
Bad debt (benefit) expense	(5,318)	10,092	24,928	23,404
Total operating expenses	1,074,813	916,516	1,868,532	1,907,254
Income (loss) from operations	74,985	(752,968)	(524,295)	(1,087,176)
Other income (expense):
Interest income	1,212	12,119	1,598	15,376
Interest expense	(63,144)	(97,254)	(125,147)	(184,034)
Net other expense	(61,932)	(85,135)	(123,549)	(168,658)
Income (loss) before income taxes	13,053	(838,103)	(647,844)	(1,255,834)
Income tax expense
Net income (loss)	13,053	(838,103)	(647,844)	(1,255,834)
Other comprehensive income - foreign currency translation adjustment	5,796	(811,164)	(191,236)	24,701
Comprehensive income (loss)	$ 18,849	$ (1,649,267)	$ (839,080)	$ (1,231,133)
Earnings (loss) per share:
Basic and diluted	$ 0	$ (0.02)	$ (0.01)	$ (0.03)
Weighted average shares outstanding	43,579,557	43,579,557	43,579,557	43,579,557

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Beginning balance at Dec. 31, 2018	$ 43,580	$ 23,590,204	$ (5,270,358)	$ 11,835,349	$ 30,198,775
Beginning balance, shares at Dec. 31, 2018	43,579,557
Net loss for the three months ended			(417,731)		(417,731)
Foreign currency translation adjustment				835,865	835,865
Ending balance at Mar. 31, 2019	$ 43,580	23,590,204	(5,688,089)	12,671,214	30,616,909
Ending balance, shares at Mar. 31, 2019	43,579,557
Beginning balance at Dec. 31, 2018	$ 43,580	23,590,204	(5,270,358)	11,835,349	30,198,775
Beginning balance, shares at Dec. 31, 2018	43,579,557
Net loss for the three months ended					(1,255,834)
Foreign currency translation adjustment					24,701
Ending balance at Jun. 30, 2019	$ 43,580	23,590,204	(6,526,192)	11,860,050	28,967,642
Ending balance, shares at Jun. 30, 2019	43,579,557
Beginning balance at Mar. 31, 2019	$ 43,580	23,590,204	(5,688,089)	12,671,214	30,616,909
Beginning balance, shares at Mar. 31, 2019	43,579,557
Net loss for the three months ended			(838,103)		(838,103)
Foreign currency translation adjustment				(811,164)	(811,164)
Ending balance at Jun. 30, 2019	$ 43,580	23,590,204	(6,526,192)	11,860,050	28,967,642
Ending balance, shares at Jun. 30, 2019	43,579,557
Beginning balance at Dec. 31, 2019	$ 43,580	23,590,204	(25,972,402)	11,576,219	9,237,601
Beginning balance, shares at Dec. 31, 2019	43,579,557
Net loss for the three months ended			(660,897)		(660,897)
Foreign currency translation adjustment				(197,032)	(197,032)
Ending balance at Mar. 31, 2020	$ 43,580	23,590,204	(26,633,299)	11,379,187	8,379,672
Ending balance, shares at Mar. 31, 2020	43,579,557
Beginning balance at Dec. 31, 2019	$ 43,580	23,590,204	(25,972,402)	11,576,219	9,237,601
Beginning balance, shares at Dec. 31, 2019	43,579,557
Net loss for the three months ended					(647,844)
Foreign currency translation adjustment					(191,236)
Ending balance at Jun. 30, 2020	$ 43,580	23,590,204	(26,620,246)	11,384,983	8,398,521
Ending balance, shares at Jun. 30, 2020	43,579,557
Beginning balance at Mar. 31, 2020	$ 43,580	23,590,204	(26,633,299)	11,379,187	8,379,672
Beginning balance, shares at Mar. 31, 2020	43,579,557
Net loss for the three months ended			13,053		13,053
Foreign currency translation adjustment				5,796	5,796
Ending balance at Jun. 30, 2020	$ 43,580	$ 23,590,204	$ (26,620,246)	$ 11,384,983	$ 8,398,521
Ending balance, shares at Jun. 30, 2020	43,579,557

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities:
Net loss	$ (647,844)	$ (1,255,834)
Depreciation and amortization	1,305,070	1,575,870
Bad debt expense	24,928	23,404
Inventory write off		111,533
Changes in assets and liabilities:
Trade accounts and other receivables	(305,183)	(284,126)
Advances to suppliers	(279,380)	(10,615)
Inventory	(14,136)	960,946
Trade accounts payable	(323,470)	223,562
Accrued taxes payable	279,748	(43,632)
Other payables and accrued expenses	(79,967)	(369,547)
Change in bankers' acceptance notes payable	115,468	(781,626)
Advances from customers	95,579	31,548
Prepaid expenses	(323,553)	(31,309)
Net Cash (Used in) Provided by Operating Activities	(152,740)	150,174
Cash Flows from Investing Activities:
Purchases of property and equipment	(840,449)	(73,538)
Net Cash Used in Investing Activities	(840,449)	(73,538)
Cash Flows from Financing Activities:
Proceeds from lines of credit	1,919,818
Payments of construction term loan	(142,209)	(147,475)
Proceeds (payments) of related party payables	90,551	(231,252)
Net Cash Provided by (Used in) Financing Activities	1,868,160	(378,727)
Effect of Exchange Rate Changes on Cash	(23,318)	768
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	851,653	(301,323)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	1,184,887	2,460,527
Cash, Cash Equivalents and Restricted Cash at End of Period	2,036,540	2,159,204
Cash and Cash Equivalents	1,813,544	1,655,892
Restricted cash	222,996	503,312
Cash, Cash Equivalents and Restricted Cash at End of Period	2,036,540	2,159,204
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	118,374	178,991
Supplemental Noncash Investing and Financing Activities:
Issuance of banker's acceptances
Accounts receivable collected with banker's acceptances	270,453	378,585
Inventory purchased with banker's acceptances	304,520	399,455
Right-of-use assets obtained in exchange for operating lease obligations		$ 233,629

Organization and Significant Ac

Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines. Liquidity and Going Concern As of June 30, 2020, the Company had cash and cash equivalents of $1.8 million and an accumulated deficit of $26.6 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.8 million at June 30, 2020 to provide working capital and enable the Company’s required payments related to its construction loan facility. Although the Company recorded a profit in the three months ended June 30, 2020, operating losses are anticipated to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8, in April 2020 the Company obtained a line of credit from a bank for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced to the Company. Also, in June 2020 the Company obtained an additional line of credit and received advances totaling RMB 8,500,000 (approximately $1.2 million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 30, 2020. Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy. Interest Rate Risk Reclassification Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: June 30, December 31, 2020 2019 Raw materials $ 1,798,405 $ 2,113,994 Work in process 644,174 314,231 Finished goods 1,410,393 1,160,599 Total Inventory $ 3,852,972 $ 3,588,824

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: June 30, December 31, 2020 2019 Permit of land use $ 397,864 $ 403,755 Building 9,239,010 9,375,817 Plant, machinery and equipment 26,757,799 26,309,262 Motor vehicle 303,835 308,334 Office equipment 216,264 217,058 Total 36,914,772 36,614,226 Less: accumulated depreciation (21,283,119 ) (20,300,399 ) Property, Plant and Equipment, net $ 15,631,653 $ 16,313,827 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended June 30, 2020 and 2019, depreciation expense was $640,473 and $762,475, respectively and $1,287,586 and $1,535,336 for the six months ended June 30, 2020 and 2019, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the National Medical Products Administration (the "NMPA", formerly China Food and Drug Administration, CFDA). The Company did not obtain NMPA production approval for any new medical formulas during the six months ended June 30, 2020 and 2019 and no costs were reclassified from advances to intangible assets during the six months ended June 30, 2020 and 2019, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $8,676 and $17,912 for the three months ended June 30, 2020 and 2019, respectively, and $17,484 and $40,534 for the six months ended June 30, 2020 and 2019, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the six months ended June 30, 2020 and 2019. Intangible assets consisted solely of NMPA approved medical formulas as follows: June 30, December 31, 2020 2019 Gross carrying amount $ 4,768,507 $ 4,839,117 Accumulated amortization (4,583,263 ) (4,633,506 ) Net carrying amount $ 185,244 $ 205,611

Advances for Purchases of Intan

Advances for Purchases of Intangible Assets	6 Months Ended
	Jun. 30, 2020
Advances for Purchases of Intangible Assets [Abstract]
ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS	NOTE 5 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS In order to expand the number of medicines the Company manufactured and marketed, it entered into contracts with independent laboratories and others for the purchase of medical formulas and assistance with the NMPA approval process. Under the new regulations and policy environment, the criteria for formulations' development are more stringent. The Company must supplement and improve the corresponding processes and standards to meet the latest requirements of NMPA in accordance with the requirements of consistency evaluation. As a result, the Company anticipates an extended timeline on the approval process of its current pipeline products. If a medical product is not approved by the NMPA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the NMPA are recorded as advances for purchases of intangible assets. To date, no formula has failed to receive NMPA production approval nor has the Company been informed or been made aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval, and if the Company does not receive such approval, it will enforce its contractual rights to receive a refund from the laboratory or have the payments applied to another medical formula with the same laboratory. The management determined to impair all remaining advances at December 31, 2019, but may resume the development of these formulas in the future if sufficient funding and other favorable conditions arise.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company's board of directors ("Board") had previously advanced to the Company an aggregate amount of $1,354,567 as of June 30, 2020 and December 31, 2019 which are recorded as "Other payables – related parties" on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense for each of the three months ended June 30, 2020 and 2019 was $3,386 and $3,386, respectively. Total interest expense for each of the three months ended June 30, 2020 and 2019 was $6,773 and $6,773, respectively. The Company received advances totaling $90,551 during the six months ended June 30, 2020 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $797,594 and $717,419 and are recorded as Other payables – related parties on the accompanying condensed consolidated balance sheets as of June 30, 2020 and December 31, 2019, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($674,405) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement was extended to July 10, 2021. Total interest expense related to the loan for the three and six months ended June 30, 2020 was $7,321 and $14,754. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheets totaling $2,315,986 and $2,307,986 as of June 30, 2020 and December 31, 2019, respectively.

Banker's Acceptance Notes Payab

Banker's Acceptance Notes Payable	6 Months Ended
	Jun. 30, 2020
Banker's Acceptance Notes Payable [Abstract]
BANKER'S ACCEPTANCE NOTES PAYABLE	NOTE 7 – BANKER'S ACCEPTANCE NOTES PAYABLE In April 2016, the Company entered into a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the banker's acceptance notes issued to the third parties. The amount of these deposited balances is shown as "Restricted cash" on the accompanying balance sheets as of June 30, 2020 and December 31, 2019. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the banker's acceptance notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. As of June 30, 2020 and December 31, 2019, the Company had outstanding banker's acceptance notes in the amount of $222,996 and $109,908, respectively.

Construction Loan Facility and

Construction Loan Facility and Line of Credit	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT	NOTE 8 – CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT Construction Loan Facility The Company obtained a construction loan facility, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company's new production facility and the included production line equipment and machinery. The loan bears interest based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The interest rate has remained at 5.39% on the anniversary dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required payments due under the loan. As of June 30, 2020, the Company had no additional amounts available to it under this facility. During the six months ended June 30, 2020, the Company made principal payments in the amount of $143,286 (RMB 1,000,000). The Company made the required RMB 14,000,000 (approximately $2 million) payment due under the loan on July 10, 2020. Lines of Credit In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced through June 30, 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has an additional RMB 5,000,000 (approximately $0.7 million) available under the line, subject to a risk review and approval by the third party guarantee company. Total interest expense under this facility for the three and six months ended June 30, 2020 was $4,953. In July 2020 an additional RMB 3,000,000 (approximately $0.4 million) has been advanced On June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest for the three and six months ended June 30, 2020 was $0. Principal payments required for the remaining terms of the loan facility and the lines of credit for the twelve month periods ended June 30, are as follows: Year Lines of Construction Total 2021 $ 1,200,650 $ 2,118,794 $ 3,319,444 2022 706,264 1,977,541 2,683,805 $ 1,906,914 $ 4,096,335 $ 6,003,249 Fair Value of Construction Loan Facility and Lines of Credit

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's incremental borrowing rate at the initial measurement date. For the three months ended June 30, 2020 and 2019, operating lease cost was $22,265 and $23,109, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $23,665 and $24,562, respectively. For the six months ended June 30, 2020 and 2019, operating lease cost was $44,494 and $46,454, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $47,292 and $49,376, respectively. As of June 30, 2020 and December 31, 2019, the Company reported operating lease right of use assets of $90,289 and $136,779, respectively and operating use liabilities of $93,510 and $140,007, respectively. As of June 30, 2020, its operating leases had a weighted average remaining lease term of 1.02 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month periods ended June 30: 2021 $ 94,585 2022 1,384 Total undiscounted cash flows 95,969 Less: Imputed interest (2,459 ) 93,510 Less: Operating lease liabilities, current portion (93,510 ) Operating lease liabilities, net of current portion $ - The Company has leases with terms of less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2019, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2016 through December 31, 2019 and the Chinese income tax return for the year ended December 31, 2019 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the three and six months ended June 30, 2020 and 2019 respectively due to continued net losses of the Company. As of June 30, 2020, the Company had net operating loss carryforwards for PRC tax purposes of approximately $51.7 million which are available to offset any future taxable income through 2025. Approximately $21.6 million of these carryforwards will expire in December 2020. The Company also has net operating losses for United States federal income tax purposes of approximately $6.4 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.3 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. Recent U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2020 and December 31, 2019. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $30,455,483 and $30,759,656 as of June 30, 2020 and December 31, 2019, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker's acceptance notes it holds at June 30, 2020 and December 31, 2019. The banker's acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at June 30, Reporting Date Using Description 2020 Level 1 Level 2 Level 3 Banker's acceptance notes $ 11,251 $ - $ 11,251 $ - Total $ 11,251 $ - $ 11,251 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2019 Level 1 Level 2 Level 3 Banker's acceptance notes $ 45,756 $ - $ 45,756 $ - Total $ 45,756 $ - $ 45,756 $ -

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS' EQUITY The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company's Board.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	NOTE 13 – REVENUE The following table summarizes the Company's revenues disaggregated by revenue source and geography based on the Company's PRC based business locations: For the Three Months For the Six Months Ended June 30, Ended June 30, 2020 2019 2020 2019 Domestic Pharmaceuticals $ 2,069,615 $ 2,569,408 $ 3,833,570 $ 5,498,681 Export Medical Test Kits 1,701,108 - 1,701,108 - $ 3,770,723 $ 2,569,408 $ 5,534,678 $ 5,498,681 There were no sales of medical test kits within the PRC. Medical test kits under this note is COVID-19 testers as referred to under Item 2 of this report.

Risks & Uncertainties

Risks & Uncertainties	6 Months Ended
	Jun. 30, 2020
Risks & Uncertainties [Abstract]
RISKS & UNCERTAINTIES	NOTE 14 – RISKS & UNCERTAINTIES Current vulnerability due to certain concentrations For the six months ended June 30, 2020, one customer accounted for 30.7% of sales and two customers respectively accounted for 49.8% and 10.7% of accounts receivable. Two suppliers respectively accounted for 39.0% and 18.6% of raw material purchases, and three different products respectively accounted for 30.8%, 21.4% and 13.9% of revenue. For the six months ended June 30, 2019, no customer accounted for more than 10% of sales and two customers respectively accounted for 49.7% and 10.7% of accounts receivable. Two suppliers respectively accounted for 27.7% and 24.7% of the Company's raw material purchases, and three different products respectively accounted for 33.9%, 21.0% and 16.1% of revenue. Nature of Operations Impact from the New Coronavirus Global Pandemic ("COVID-19") Economic environment - In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Organization and Significant _2

Organization and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.
Liquidity and Going Concern	Liquidity and Going Concern As of June 30, 2020, the Company had cash and cash equivalents of $1.8 million and an accumulated deficit of $26.6 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $0.8 million at June 30, 2020 to provide working capital and enable the Company’s required payments related to its construction loan facility. Although the Company recorded a profit in the three months ended June 30, 2020, operating losses are anticipated to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative organization. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. As discussed in Note 8, in April 2020 the Company obtained a line of credit from a bank for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced to the Company. Also, in June 2020 the Company obtained an additional line of credit and received advances totaling RMB 8,500,000 (approximately $1.2 million). While the current plans and additional financing will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 30, 2020.
Accounting Estimates	Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
Credit Risk	Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.
Interest Rate Risk	Interest Rate Risk
Reclassification	Reclassification
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes". From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventory	June 30, December 31, 2020 2019 Raw materials $ 1,798,405 $ 2,113,994 Work in process 644,174 314,231 Finished goods 1,410,393 1,160,599 Total Inventory $ 3,852,972 $ 3,588,824

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	June 30, December 31, 2020 2019 Permit of land use $ 397,864 $ 403,755 Building 9,239,010 9,375,817 Plant, machinery and equipment 26,757,799 26,309,262 Motor vehicle 303,835 308,334 Office equipment 216,264 217,058 Total 36,914,772 36,614,226 Less: accumulated depreciation (21,283,119 ) (20,300,399 ) Property, Plant and Equipment, net $ 15,631,653 $ 16,313,827
Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets	Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	June 30, December 31, 2020 2019 Gross carrying amount $ 4,768,507 $ 4,839,117 Accumulated amortization (4,583,263 ) (4,633,506 ) Net carrying amount $ 185,244 $ 205,611

Construction Loan Facility an_2

Construction Loan Facility and Line of Credit (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of principal payments	Year Lines of Construction Total 2021 $ 1,200,650 $ 2,118,794 $ 3,319,444 2022 706,264 1,977,541 2,683,805 $ 1,906,914 $ 4,096,335 $ 6,003,249

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of minimum lease payments for the company's operating leases liabilitie	2021 $ 94,585 2022 1,384 Total undiscounted cash flows 95,969 Less: Imputed interest (2,459 ) 93,510 Less: Operating lease liabilities, current portion (93,510 ) Operating lease liabilities, net of current portion $ -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value	Fair Value Measurements at June 30, Reporting Date Using Description 2020 Level 1 Level 2 Level 3 Banker's acceptance notes $ 11,251 $ - $ 11,251 $ - Total $ 11,251 $ - $ 11,251 $ - Fair Value Measurements at December 31, Reporting Date Using Description 2019 Level 1 Level 2 Level 3 Banker's acceptance notes $ 45,756 $ - $ 45,756 $ - Total $ 45,756 $ - $ 45,756 $ -

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of revenues disaggregated by revenue source and geography	For the Three Months For the Six Months Ended June 30, Ended June 30, 2020 2019 2020 2019 Domestic Pharmaceuticals $ 2,069,615 $ 2,569,408 $ 3,833,570 $ 5,498,681 Export Medical Test Kits 1,701,108 - 1,701,108 - $ 3,770,723 $ 2,569,408 $ 5,534,678 $ 5,498,681

Organization and Significant _3

Organization and Significant Accounting Policies (Details) - USD ($)	Apr. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	May 25, 2005
Organization and Significant Accounting Policies (Textual)
Cash and cash equivalents		$ 1,800,000		$ 1,800,000
Accumulated deficit		26,600,000		26,600,000
Bad debt expense		(5,318)	$ 10,092	24,928	$ 23,404
Advances from customers		592,961		592,961		$ 505,398
Line of credit, description	Line of credit from a bank for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced to the Company. Also, in June 2020 the Company obtained an additional line of credit and received advances totaling RMB 8,500,000 (approximately $1.2 million).
Management [Member]
Organization and Significant Accounting Policies (Textual)
Working capital		$ 800,000		$ 800,000
British Virgin Islands Corporation [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage		100.00%		100.00%
Nevada Corporation [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage		100.00%		100.00%
Onny [Member]
Organization and Significant Accounting Policies (Textual)
Equity method investment, ownership percentage							100.00%

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,798,405	$ 2,113,994
Work in process	644,174	314,231
Finished goods	1,410,393	1,160,599
Total Inventory	$ 3,852,972	$ 3,588,824

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Permit of land use	$ 397,864	$ 403,755
Building	9,239,010	9,375,817
Plant, machinery and equipment	26,757,799	26,309,262
Motor vehicle	303,835	308,334
Office equipment	216,264	217,058
Total	36,914,772	36,614,226
Less: accumulated depreciation	(21,283,119)	(20,300,399)
Property, Plant and Equipment, net	$ 15,631,653	$ 16,313,827

Property, Plant and Equipment_3

Property, Plant and Equipment (Details 1)	6 Months Ended
	Jun. 30, 2020
Minimum [Member] | Permit of land use [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years
Minimum [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	20 years
Minimum [Member] | Plant, machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Motor vehicle [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Office equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum [Member] | Permit of land use [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	70 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	49 years
Maximum [Member] | Plant, machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Motor vehicle [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Office equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

Property, Plant and Equipment_4

Property, Plant and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment (Textual)
Depreciation expense	$ 640,473	$ 762,475	$ 1,287,586	$ 1,535,336

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Intangible assets consisted solely of NMPA approved medical formulas as follows:
Gross carrying amount	$ 4,768,507	$ 4,839,117
Accumulated amortization	(4,583,263)	(4,633,506)
Net carrying amount	$ 185,244	$ 205,611

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Intangible Assets (Textual)
Amortization expense relating to intangible assets	$ 8,676	$ 17,912	$ 17,484	$ 40,534
Intangible assets useful life , description			NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.

Related Party Transactions (Det

Related Party Transactions (Details)	Jul. 08, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Jul. 08, 2019CNY (¥)
Related Party Transactions (Textual)
Interest rate		1.00%		1.00%
Interest expense		$ 3,386	$ 3,386	$ 6,773	$ 6,773
Other payables - related parties aggregate amount		1,354,567		1,354,567		$ 1,354,567
Other payables		2,315,986		2,315,986		2,307,986
Other payables related parties		797,594		797,594		$ 717,419
Management [Member]
Related Party Transactions (Textual)
Interest rate	4.35%						4.35%
Interest expense		7,321		14,754
Other payables - related parties aggregate amount		$ 90,551		$ 90,551
Loan agreement to borrow cash	$ 674,405
Loan agreement payable term	1 year
Management [Member] | RMB [Member]
Related Party Transactions (Textual)
Loan agreement to borrow cash | ¥							¥ 4,770,000

Banker's Acceptance Notes Pay_2

Banker's Acceptance Notes Payable (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Banker's Acceptance Notes Payable (Textual)
Maximum amount of agreement	$ 4,500,000
Agreement payments fees, description	In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank.
Banker's acceptance notes payable outstanding	$ 222,996	$ 109,908
RMB [Member]
Banker's Acceptance Notes Payable (Textual)
Maximum amount of agreement	$ 30,000,000

Construction Loan Facility an_3

Construction Loan Facility and Line of Credit (Details)	Jun. 30, 2020USD ($)
2020	$ 3,319,444
2021	2,683,805
Total	6,003,249
Line of Credit [Member]
2020	1,200,650
2021	706,264
Total	1,906,914
Construction Loan Facility [Member]
2020	2,118,794
2021	1,977,541
Total	$ 4,096,335

Construction Loan Facility an_4

Construction Loan Facility and Line of Credit (Details Textual)	Apr. 30, 2020USD ($)	Jul. 31, 2020	Apr. 30, 2020USD ($)	Jun. 21, 2013USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020CNY (¥)	Apr. 20, 2020USD ($)	Jun. 21, 2013CNY (¥)
Construction loan amount	$ 1,400,000		$ 1,400,000	$ 13,000,000	$ 8,500,000		$ 8,500,000
Description of loan interest rates			The loan bears interest at a rate of 4.25% per annum.	The loan bears interest based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The interest rate has remained at 5.39% on the anniversary dates which were July 10, 2017, 2018 and 2019, respectively. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015.			The loan bears interest at the rate of 4.05% per annum.
Principal amount	$ 700,000		$ 700,000		143,286		$ 143,286
Payment due under the loan				$ 2,000,000
Laon facility term			Advances on the line of credit are due two years from the date of the advance.				The line of credit is due in one year on the anniversary date of the line of credit.
Total interest expense					63,144	$ 97,254	$ 125,147	$ 184,034
Line of credit, description	Line of credit from a bank for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) have been advanced to the Company. Also, in June 2020 the Company obtained an additional line of credit and received advances totaling RMB 8,500,000 (approximately $1.2 million).
Subsequent Event [Member]
Line of credit, description		Additional RMB 3,000,000 (approximately $0.4 million) has been advanced under this line of credit. The Company has an additional RMB 2,000,000 (approximately $0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company.
Postal Savings Bank of China [Member]
Total interest expense							4,953
Bank of Communications [Member]
Total interest expense					0		0
RMB [Member]
Construction loan amount					$ 1,200,000		$ 1,200,000			$ 10,000,000	¥ 80,000,000
Principal amount									¥ 1,000,000	$ 5,000,000
Payment due under the loan				$ 14,000,000

Leases (Details)

Leases (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 94,585
2022	1,384
Total undiscounted cash flows	95,969
Less: Imputed interest	(2,459)
Total Lease Liability	93,510	$ 140,007
Less: Operating lease liabilities, current portion	93,510	91,306
Operating lease liabilities, net of current portion		$ 48,701

Leases (Details Textual)

Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Dec. 31, 2019
Leases (Textual)
Operating leases cost	$ 22,265	$ 23,109	$ 44,494	$ 46,454
Cash flows from operating leases	23,665	$ 24,562	47,292	49,376
Operating lease right of use assets	90,289		90,289	136,779
Operating leases liabilities	$ 93,510		$ 93,510	$ 140,007
Weighted average remaining lease term	1 year 7 days		1 year 7 days
Weighted average discount rate	4.75%		4.75%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Income Taxes (Textual)
Net operating loss carryforwards for PRC tax	$ 51,700,000
Operating loss, expiration date	Dec. 31, 2025
Valuation allowance for deferred tax assets	$ 30,455,483	$ 30,759,656
Enterprise income tax rate	25.00%
Net operating loss expiration, description	Approximately $51.7 million which are available to offset any future taxable income through 2025. Approximately $21.6 million of these carryforwards will expire in December 2020. The Company also has net operating losses for United States federal income tax purposes of approximately $6.4 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.3 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
Description of federal corporate income tax rate	The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fair Value Inputs Assets Quantitatives Information [Line Items]
Banker's acceptance notes	$ 11,251	$ 45,756
Total	11,251	45,756
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs Assets Quantitatives Information [Line Items]
Banker's acceptance notes
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs Assets Quantitatives Information [Line Items]
Banker's acceptance notes	11,251	45,756
Total	11,251	45,756
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs Assets Quantitatives Information [Line Items]
Banker's acceptance notes
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Stockholders' Equity (Textual)
Common stock, shares authorized	95,000,000	95,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue	$ 3,770,723	$ 2,569,408	$ 5,534,678	$ 5,498,681
Domestic Pharmaceuticals [Member]
Revenue	2,069,615	2,569,408	3,833,570	5,498,681
Export Medical Test Kits [Member]
Revenue	$ 1,701,108		$ 1,701,108

Risks & Uncertainties (Details)

Risks & Uncertainties (Details)	6 Months Ended
	Jun. 30, 2020CustomerSuppliers / Number	Jun. 30, 2019CustomerSuppliers / Number
Sales Revenue, Net [Member]
Concentrations (Textual)
Concentrations risk, percentage	30.70%	10.00%
Number of customers	1	0
Accounts Receivable [Member]
Concentrations (Textual)
Number of customers	2	2
Accounts Receivable [Member] | Customer [Member]
Concentrations (Textual)
Concentrations risk, percentage	49.80%	49.70%
Accounts Receivable [Member] | Customer One [Member]
Concentrations (Textual)
Concentrations risk, percentage	10.70%	10.70%
Raw Material Purchases [Member]
Concentrations (Textual)
Number of suppliers | Suppliers / Number	2	2
Raw Material Purchases [Member] | Suppliers [Member]
Concentrations (Textual)
Concentrations risk, percentage	39.00%	27.70%
Raw Material Purchases [Member] | Suppliers One [Member]
Concentrations (Textual)
Concentrations risk, percentage	18.60%	24.70%
Revenue one [Member]
Concentrations (Textual)
Concentrations risk, percentage	30.80%	33.90%
Revenue two [Member]
Concentrations (Textual)
Concentrations risk, percentage	21.40%	21.00%
Revenue three [Member]
Concentrations (Textual)
Concentrations risk, percentage	13.90%	16.10%